Lisdexamfetamine dimesylate
SPD489-404
Approved small_molecule completed
Quick answer
Lisdexamfetamine dimesylate for Attention Deficit Hyperactivity Disorder (ADHD) is a Approved program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Attention Deficit Hyperactivity Disorder (ADHD)
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed